Business
Theralase Anti-Cancer Drugs Independently Reviewed
Theralase Anti-Cancer Drugs Independently Reviewed Toronto, Ontario (FSCw...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Anti-Cancer Drugs Independently Reviewed \n\t\t\tbody { font-size: 11pt;\n\t\t\t}\n\n\t\t\t.nr-sub-head ul,\n\t\t\t.nr-body ul {\n\t\t\t\tlist-style-type: disc !important;\n\t\t\t\tmargin-left: 2em !important;\n\t\t\t}\n\n\t\t\t.nr-sub-head ol,\n\t\t\t.nr-body ol {\n\t\t\t\tmargin-left: 2em !important;\n\t\t\t}\n\n\t\t\t.nr-body p, .nr-body {margin-bottom: 0px !important;\n\t\t\t\t\tmargin-top: 0px !important;\n\t\t\t\t\t-webkit-margin-before: 0px !important;\n\t\t\t\t\t-webkit-margin-after: 0px !important;\n\t\t\t\t\tfont-family: Arial !important;\n\t\t\t\t\tfont-size: 11pt !important;\n\t\t\t }\n\n\t\t\ttbody {\n\t\t\t\tborder-top: 0;\n\t\t\t}\n\n\t\t\t H1 {font-weight: bold;\n\t\t\t\tfont-size: 16pt;\n\t\t\t }\n\n\t\t\t H2 {font-weight: bold;\n\t\t\t\tfont-size: 12pt;\n\t\t\t }\n\n\t\t\t H3 {font-weight: bold;\n\t\t\t\tfont-size: 11pt;\n\t\t\t }\n\n\n\t\t\t H1.nr-head {\n\t\t\t \t\tfont-family: Trebuchet MS !important;\n\t\t\t \t\tfont-size: 16pt !important;\n\t\t\t \t\tcolor: #3D86C6 !important;\n\t\t\t \t\tfont-weight:bold !important;\n\t\t\t \t\ttext-align:center !important;\n\n\t\t\t }\n\n\t\t\t H2.nr-sub-head {font-weight: bold !important;\n\t\t\t \t\tdisplay: block !important;\n\t\t\t \t\ttext-align: start !important;\n\t\t\t \t\tfont-family: Arial !important;\n\t\t\t\t\tfont-size: 12pt !important;\n\t\t\t }\n\n\t\t\t .nr-body a { font-size: 11pt !important;\n\t\t\t }\n\n\t\t\t TABLE { width: auto!important;\n\t\t\t }\n\n\t\t Theralase Anti-Cancer Drugs Independently Reviewed\n Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that a recent peer-reviewed paper entitled, “Novel Osmium-based Coordination Complexes as Photosensitizers for Panchromatic Photodynamic Therapy”, presenting research on Theralase licensed Osmium PDCs, has been independently reviewed by Dr. Edith C. Glazer in her recent paper entitled, “Panchromatic Osmium Complexes for Photodynamic Therapy: Solutions to Existing Problems and New Questions”.\n\n \n\nEdith C. Glazer, Ph.D., Associate Professor, Department of Bio...